Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI
Omalizumab can regulate most cytokine and chemokine levels in responders. However, in nonresponders, it is unable to modulate specific proasthmatic cytokines and chemokines due to their association with individual body mass index, which is not influenced by omalizumab.
Authors
- SangKon Oh (ORCID: https://orcid.org/0000-0003-0813-5244)
- Chao Gu (ORCID: https://orcid.org/0000-0001-9285-8108)
- HyeMee Joo (ORCID: https://orcid.org/0000-0002-9440-9389)
- Katherine Upchurch (ORCID: https://orcid.org/0000-0002-9813-3949)
- Laurie Baert (ORCID: https://orcid.org/0000-0001-8309-7132)
- Mark Millard
- Agnes Yang
- Adrien Caffiers
Institutions
- Baylor University (US)
- Baylor University Medical Center (US)
- WinnMed (US)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-03-23
- DOI
- https://doi.org/10.1016/j.jacig.2025.100462
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Mayo Foundation for Medical Education and Research
- American Asthma Foundation
- Genentech